



MANHATTAN SCIENTIFICS, INC.

OTC: BB MHTX

The Chrysler Building
405 Lexington Avenue, 26th floor
New York • NY • 10174 • Tel: (212) 541.2405
<http://www.mhtx.com/>

IR & PR CONTACTS

• **Marvin Maslow, Founder**

T: (917) 923.3300

E: marvin@mhtx.com

• **Alex Stanton**

Stanton Public Relations and Marketing

T: (212) 780-0701

• **Hawk Associates**

W: <http://www.hawkassociates.com/>

EXECUTIVE CONTACT

• **Manny Tsoupanarias, CEO**

T: (918) 919.0370

E: mtsoupanarias@manhattanscientifics.com

TECHNICAL CONTACTS

• **Metals Project**

• **Terry C. Lowe**

T: (505) 670.8755

E: tlowe@mhtx.com

• **Cancer Project**

• **Edward R. Flynn**

T: (505) 247.0602

E: erf@seniorscientific.com

Senior Scientific: <http://www.seniorscientific.com/>

ABOUT MANHATTAN SCIENTIFICS

Manhattan Scientifics Inc. (www.mhtx.com) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.

The Company's business model capitalizes on inventions and technology from which profits could be earned primarily through licensing. MHTX is dedicated to earning profit for its 8,600 owner-shareholders by identifying, developing, patenting, supporting and marketing technical innovation by harvesting top technology talent to bring game-changing products to market.

Manhattan Scientifics assists and acquires early stage technologies and assists entrepreneurial founders and management to stage them to become commercial. Our investment philosophy is defined by our desire to help build innovative companies with exceptional potential. We emphasize novel technologies in the nano-medicine space with the potential to be disruptive and the ability to establish sustainable businesses. We are patient capital with experienced business-building partners who bring the perspective of merchant-bankers not venture capitalists. Our approach to assist scientists to commercialize their work is by providing a forum within which the commercialization process is fostered through partnerships with existing companies (Fortune 1000 or larger). The entrepreneurial scientists and engineers who join us create personal success and wealth on an accelerated basis by virtue of ownership of publicly traded Manhattan Scientifics shares (MHTX).

Manhattan Scientifics distinguishes itself from most venture capital firms in that it uses its own, rather than managed capital. Consequently, Manhattan Scientifics' actions are not constrained by preset rules and fund-life-time tables, and the technologist avoids many of the sometimes-adversarial aspects of venture capital relationships. Technologists who are "partnered" with our company also enjoy the diversity of shared success with their brother technologists at Manhattan Scientifics - success at any one of the company's technologies finds its way into the value of our shares, and that success is shared by the entrepreneur whose concept or acceptance in the market place has not yet matured. Manhattan Scientifics brings its expertise with capital, but also with talent including IP counsel, experienced marketers and networkers with global reach.

Manhattan Scientifics believes that the ideal route to commercial success for a new or emerging technology is by "hitching one's wagon to a star" - joining with one or more major companies who possess the deep pockets necessary to manufacture and market.

Such companies allow the new technology to avoid the many pitfalls of the "Do it yourself" approach of startups (most of which fail). Our company earns profit through royalty-bearing licenses as part of the technology transfer process.

THE ULTRA FINE METALS PROJECT

Manhattan Scientifics owns the exclusive, perpetual USA license to a family of patents which will enable the marketing of super strong, ultra-fine grain "nanostructured" metals that have been developed at the Los Alamos National Laboratory (LANL) and in the former Soviet Union. These new metals defy the rules that have limited the capability of all other metals. (Please see the video on the Company's website: www.mhtx.com, go to "Media").

The Company's process will enable double-strength metals and alloys, with a fraction of the weight i.e. aluminum as strong as steel. The Company's nano-titanium product, now licensed to its major industrial partner, Carpenter Technology Corporation (NYSE: CRS) will enable a new family of medical devices and prosthetics with capability of bonding to human bone tissue up to 20x faster and stronger than present day products. In December, 2008, the FDA approved the use of the Company's nano-titanium alloy with dental implants manufactured in the Company's affiliated factory in Albuquerque, NM (See press release of 12/09/08).

Nanostructured cardio vascular stents will be up to 10x thinner, less prone to failure, easier to manufacture, and easier for surgeons to place in our bodies. For bone implants, the MHTX process called, "Nano structuring", applicable to virtually ALL metals, alters the materials already in use so that they sustain twice the load capacity and integrate with bone up to 20 times faster than conventional prosthetics. FDA approval will be required for each medical application.

Manhattan Scientifics & Carpenter Technology Corp. are together exploring the medical, sports and aerospace industries and other down-the-road applications targeting the transportation industry where doubly strong, lightweight materials hold the promise of dramatically and positively impacting fuel economy and performance of any vehicle that moves, i.e. cars, ships, trucks, and aircrafts. Fuel economy will be achieved by placing airplanes and other vehicles on a diet, removing thousands of pounds while maintaining full structural strength.

THE NANO-MEDICINE CANCER PROJECT

Following a 2-year exclusive license, on June 6, 2011 Manhattan Scientifics (OTC: MHTX) announced its acquisition of Senior Scientific LLC, the body of bio-magnetic detection of cancer technology developed by Edward R. Flynn, Ph.D and supported by the National Institute of Health (NIH). Dr. Flynn's magnetic field sensors make it possible to identify and image small clusters of cancer cells substantially increasing the sensitivity for finding cancer at a far earlier stage than is currently available, without the use of ionizing radiation or large magnetic fields. The bio-magnetic sensor method is applicable to breast, prostate, ovarian, leukemia, melanoma and other cancers. Prior to June, 2011, Dr. Flynn's research has been funded (for 8 years) by the NIH; Manhattan Scientifics seamlessly continued funding the research thereafter and intends to identify one or more industrial partners in the Big Pharma group and in the Medical Imaging group, to bring product to the market under royalty-bearing licenses. The process and the challenge is to move from "good science" to "good medicine". The company introduced the breakthrough technology in very early cancer detection and treatment to M.D, Anderson Cancer Center, Houston, in the spring of 2011. It was received with rave reviews. The technology was also very positively reviewed by Dr. Larry Norton, MD of the Memorial Sloan Kettering Cancer Center in Manhattan. (Please [click here](#) to see the review letter) We seek interim investors in order to accelerate progress while MD Anderson & Sloan Kettering hospitals solicit grants, investors and foundations to bring substantial financing to our project. (i.e. Susan G. Komen Foundation, Susan G. Komen for the Cure®, the global leader of the breast cancer movement, having invested more than \$1.9 billion since inception in 1982.) . We are also addressing the Big Pharma and the Medical Imaging corporations where well-capitalized companies will be selected by us as industrial partners to provide capital to accomplish the "heavy lifting" and accelerate bringing product to the market. **Our goal is to help cure cancer.**



Below one can see the 10 year historical chart and the current 1-year chart of MHTX:

10 YEAR HISTORICAL CHART



1 YEAR CURRENT CHART



Our Science Team includes technology leaders, such as Dr. Martin Cooper, inventor of the cell phone, Dr. Edward R. Flynn, founder of Senior Scientific LLC, Dr. Arthur Kaufman, founder of H-Power, Donald J. Sandstrom, former Division Leader (Ret), Materials Science, LANL, Dr. Terry C. Lowe, founder, Metallicum, Inc. (see our people at www.mhtx.com) to guide our commercial introduction of disruptive technical innovations. The Company's acquisition of Metallicum Inc. in 2008 marked a sea-change away from its previous focus on alternative energy systems. The Company and its industrial partner are exploring commercial applications of a new generation of metals designed to transform the biomedical device industry and the transportation industry, in much the same way as our own Martin Cooper changed the telephone from the original Alexander Graham Bell invention. Similarly, MHTX is forging ahead to transition Edward R. Flynn's very early cancer detection and treatment technology from "bench to bedside" in much the same way as Dr. Jonas Salk ended polio.

MANAGEMENT TEAM & COMPANY CONTACTS

- Emmanuel Tsoupanarias, Chairman & CEO
- Marvin Maslow, Founder & Chairman Emeritus
- Leonard Friedman, Esq., Director
- Frank Georgiou, Director
- Larry Schatz, Director
- Chris Theoharis, Director

Securities Counsel

- Peter DiChiara, Esq.
T: (212) 930.9700
E: pdichiara@srff.com
- Sichenzia Ross Friedman, Ference

Patent Counsel

- V. Gerald Grafe, Esq.
E: grafe@grafelawpc.com

Auditor

- PMB Helin Donovan
T: (509) 747.0468

Transfer Agent

- Interwest Securities

COMPANY DESCRIPTION & HISTORY

In its early years, Manhattan Scientifics' market cap reached \$900 million as its share price approached \$9.00. These lofty heights ended when the Nasdaq bubble broke in year 2000. Today MHTX sells at a fraction of its former levels, yet the company's fundamentals are substantially stronger than at any time during its history. Management is dedicated to restore shareholder value. The MHTX business model, acquiring, patenting, demonstrating and licensing to a major industrial deep pocket partner has been proven with the culmination of the Carpenter relationship in mid-2009. The Company will continue to incubate & commercialize world changing technologies bringing product to market and profit to its shareholders.



The foregoing document contains forward-looking statements which are subject to risk and uncertainty which may be beyond the company's control.